Anand Uma, Pacchetti Barbara, Anand Praveen, Sodergren Mikael Hans
Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK.
EMMAC Life Sciences Ltd, 57-61 Mortimer Street, London W1W 8HS, UK.
Pain Manag. 2021 Apr;11(4):395-403. doi: 10.2217/pmt-2020-0110. Epub 2021 Mar 11.
The recent legalization of medicinal cannabis in several jurisdictions has spurred the development of therapeutic formulations for chronic pain. Unlike pure delta-9-tetrahydrocannabinol (THC), full-spectrum products contain naturally occurring cannabinoids and have been reported to show improved efficacy or tolerability, attributed to synergy between cannabinoids and other components in the cannabis plant. Although 'synergy' indicates that two or more active compounds may produce an additive or combined effect greater than their individual analgesic effect, potentiation of the biological effect of a compound by related but inactive compounds, in combination, was termed the 'entourage effect'. Here, we review current evidence for potential synergistic and entourage effects of cannabinoids in pain relief. However, definitive clinical trials and functional studies are still required.
近期,多个司法管辖区将药用大麻合法化,这推动了慢性疼痛治疗配方的研发。与纯δ-9-四氢大麻酚(THC)不同,全谱产品含有天然存在的大麻素,据报道其疗效或耐受性有所改善,这归因于大麻素与大麻植物中其他成分之间的协同作用。尽管“协同作用”表明两种或更多活性化合物可能产生大于其各自镇痛作用的相加或联合效应,但相关但无活性的化合物组合对一种化合物生物效应的增强作用则被称为“随行效应”。在此,我们综述了大麻素在缓解疼痛方面潜在协同作用和随行效应的现有证据。然而,仍需要进行确定性的临床试验和功能研究。